Verastem, Inc.
VS-7375
advanced KRAS G12D solid tumors
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for VS-7375 in advanced KRAS G12D solid tumors are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027.”